A Valeant Update: Damaged Goods or Deeply Discounted Drug Company?

96 Normal 0 false false false EN-US X-NONE X-NONE ...

Read More

January 2017 Data Update 10: The Pricing Game!

It's taken me a while to get here, but in this, the last of my ten posts looking at publicly traded companies globally, I look at pricing differences across regions and sectors. I laid out my rationale for looking at pricing in my most recent post on the topic, where I drew...

Read More

Explaining a Paradox: Why Good (Bad) Companies can be Bad (Good) Investments!

In nine posts, stretched out over almost two months, I have tried to describe how companies around the world make investments, finance them and decide how much cash to return to shareholders. Along the way, I have argued that a preponderance of publicly traded companies, across...

Read More